Skip to main content
. Author manuscript; available in PMC: 2022 Mar 25.
Published in final edited form as: Clin Cancer Res. 2017 Nov 27;24(5):1114–1123. doi: 10.1158/1078-0432.CCR-17-1193

Figure 5. Chimeric BAFF-R antibodies induced ADCC on drug insensitive/resistant lymphoma models in vitro.

Figure 5.

(A) Verification of JeKo-1 cells following CRISPR/HDR knock-out of CD20 gene compared with JeKo-1 wildtype (WT). FACS analysis showed CD20 binding on selected clone and WT. Viability and doubling time of JeKo-1-CD20-KO cells were monitored over 20 passages. ADCC effects measured by chromium-51 release after incubation with C55, C90, or rituximab and effectors NK cells (E:T = 20:1). Percentage of cell specific lysis of target cells: (B) rituximab-resistant JeKo-1-CD20-KO and (C) ibrutinib-resistant Z-138 and SP49-IR. All data are representative of two or more identical experiments. Data are shown as the mean ± s.d. of triplicate samples. * P < 0.05 compared with NK cells by two-tailed Student’s t-test.